Clinical Report: Stereotactic Body Radiotherapy for Untreated Mucosal SCC

Background

Locally advanced head and neck cancer (LAHNC) has a poor overall survival rate, particularly in elderly patients who are often unfit for aggressive treatments. Conventional palliative radiotherapy offers limited symptom relief and is not always well tolerated.

Data Highlights

No numerical data provided in the source material.

Key Findings

• SBRT was administered at doses ranging from 35 to 50 Gy in 5 fractions.
• The study included patients diagnosed with primary mucosal SCC who were unsuitable for radical treatment.
• Patient characteristics and treatment outcomes were extracted from electronic medical records.
• The treatment was well tolerated by frail patients with poor performance status.

Clinical Implications

The findings from this analysis suggest that SBRT could be a viable treatment option for elderly or frail patients with untreated mucosal SCC who cannot tolerate conventional therapies. Further studies are needed to establish its role in standard treatment protocols.

Conclusion

SBRT appears to be a promising alternative for patients with untreated mucosal SCC of the head and neck, particularly for those unfit for more aggressive treatment options.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. the asco post — Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma
3. The ASCO Post — Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
4. The ASCO Post — Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
5. The ASCO Post — Primary Lung Tumor SBRT Followed by Concurrent Mediastinal Chemoradiotherapy and Immunotherapy Consolidation in Locally Advanced NSCLC
6. NCCN Guidelines® Insights: Head and Neck Cancers, Version 2.2025
7. Reduced Elective Dose in Definitive Radiotherapy for Head and Neck Squamous Cell Carcinoma
8. Primary Lung Tumor SBRT Followed by Mediastinal Chemoradiotherapy in Locally Advanced NSCLC
9. Nivolumab in Squamous Cell Carcinoma of the Head and Neck in CheckMate 141: Game Not Over
10. Stereotactic Body Radiotherapy (SBRT) of Previously Unirradiated Mucosal Head and Neck Squamous Cell Carcinoma (SCC) - PubMed
11. Defining the Role of SABR in Head and Neck Cancer: Results from a Multi-institutional Delphi Consensus - ScienceDirect